Emerging Therapies for Soft-Tissue Sarcomas

Hematology/Oncology Clinics of North America

Volumn 27, Issue 5, 2013, Pages 1063-1078

  Levard, Alice ^a   Tassy, Louis ^a   Cassier, Philippe A ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Cancer; Drug development; Sarcoma; Therapy; Tumor

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ALDOXORUBICIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRIVANIB; CEDIRANIB; CISPLATIN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ERIBULIN; EVEROLIMUS; FIGITUMUMAB; GEMCITABINE; IFOSFAMIDE; MORAB 004; OMBRABULIN; PALBOCICLIB; PANOBINOSTAT; PLACEBO; POMALIDOMIDE; RAPAMYCIN; RIDAFOROLIMUS; SORAFENIB; TEMSIROLIMUS; TH 302; TIVOZANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALVEOLAR SOFT PART SARCOMA; ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; COHORT ANALYSIS; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIPOSARCOMA; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; OSTEOSARCOMA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SARCOMA; SOFT TISSUE SARCOMA; SOLITARY FIBROUS TUMOR; STOMATITIS; THROMBOCYTOPENIA; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; VASCULAR TUMOR;

CANCER; DRUG DEVELOPMENT; SARCOMA; THERAPY; TUMOR;

HUMANS; SARCOMA;

EID: 84884955405     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.07.011     Document Type: Review

References (63)

1. Schöffski P., Ray-Coquard I.L., Cioffi A., et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 2011, 12:1045-1052.
2. Van Glabbeke M., Verweij J., Judson I., et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002, 38:543-549.
3. Ganjoo K.N., Cranmer L.D., Butrynski J.E., et al. Aphase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology 2011, 80:50-56.
4. Chawla SP, Chua V, Hendifar A, etal. Phase Ib/II study of INNO-206 (EMCH-doxorubicin) in patients with soft tissue sarcoma. ASCO Meeting Abstracts. 2013.
5. George S., Blay J.Y., Casali P.G., et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009, 45:1959-1968.
6. Tariq M.S., Agresta S., Vigil C.E., et al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer 2011, 129:1963-1969.
7. Maki R.G., D'Adamo D.R., Keohan M.L., et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. JClin Oncol 2009, 27:3133-3140.
8. Bertuzzi A., Stroppa E.M., Secondino S., et al. Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy. JClin Oncol (Meeting Abstracts) 2010, 28:10025.
9. Ryan C.W., Von Mehren M., Rankin C.J., et al. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. JClin Oncol (Meeting Abstracts) 2008, 26:10532.
10. D'Adamo D.R., Keohan M.L., Carvajal R.D., et al. Aphase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST). JClin Oncol (Meeting Abstracts) 2011, 29:10025.
11. Meyer J.M., Perlewitz K.S., Hayden J.B., et al. Phase I study of neoadjuvant chemoradiation (CRT) plus sorafenib (S) for high-risk extremity soft tissue sarcomas (STS). JClin Oncol (Meeting Abstracts) 2012, 30:10011.
12. DeLaney T.F., Spiro I.J., Suit H.D., et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2003, 56:1117-1127.
13. Pisters P.W., Patel S.R., Prieto V.G., et al. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. JClin Oncol 2004, 22:3375-3380.
14. Verschraegen C.F., rias-Pulido H., Lee S.J., et al. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol 2012, 23:785-790.
15. D'Adamo D.R., Anderson S.E., Albritton K., et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. JClin Oncol 2005, 23:7135-7142.
16. Yoon S.S., Duda D.G., Karl D.L., et al. Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2011, 81:1081-1090.
17. Ratain M.J., Schwartz G.K., Oza A.M., et al. Brivanib (BMS-582664) in advanced solid tumors (AST): results of a phase II randomized discontinuation trial (RDT). JClin Oncol (Meeting Abstracts) 2011, 29:3079.
18. Schwartz G.K., Maki R.G., Ratain M.J., et al. Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): biomarker and subset results of a phase II randomized discontinuation trial. JClin Oncol (Meeting Abstracts) 2011, 29:10000.
19. Hernando E., Charytonowicz E., Dudas M.E., et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007, 13:748-753.
20. Gutierrez A., Snyder E.L., Marino-Enriquez A., et al. Aberrant AKT activation drives well-differentiated liposarcoma. Proc Natl Acad Sci USA 2011, 108:16386-16391.
21. Friedrichs N., Trautmann M., Endl E., et al. Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma. Int J Cancer 2011, 129:1564-1575.
22. Setsu N., Yamamoto H., Kohashi K., et al. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas. Cancer 2012, 118:1637-1648.
23. Barretina J., Taylor B.S., Banerji S., et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010, 42:715-721.
24. Schuetze S.M., Zhao L., Chugh R., et al. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. Eur J Cancer 2012, 48:1347-1353.
25. Richter S., Pink D., Hohenberger P., et al. Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST. JClin Oncol (Meeting Abstracts) 2010, 28:10038.
26. Quek R., Wang Q., Morgan J.A., et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 2011, 17:871-879.
27. Naing A., LoRusso P., Fu S., et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 2012, 18:2625-2631.
28. Schwartz G.K., Tap W.D., Qin L.X., et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol 2013, 14:371-382.
29. Kutko M.C., Glick R.D., Butler L.M., et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma invitro. Clin Cancer Res 2003, 9:5749-5755.
30. Ito T., Ouchida M., Ito S., et al. SYT, a partner of SYT-SSX oncoprotein in synovial sarcomas, interacts with mSin3A, a component of histone deacetylase complex. Lab Invest 2004, 84:1484-1490.
31. Sakimura R., Tanaka K., Nakatani F., et al. Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer 2005, 116:784-792.
32. Cassier P.A., Lefranc A., Penel N., et al. Efficacy and safety of panobinostat (LBH-589), a histone-deacetylase inhibitor (HDACi), in patients (pts) with advanced, previously treated soft tissue sarcoma (STS) and sex cord tumors (SCT): a study from the French Sarcoma Group. JClin Oncol (Meeting Abstracts) 2012, 30:10027.
33. Schmitt T., Andres B., Liu L., et al. Pharmacokinetic analyses of vorinostat in patients with metastatic soft tissue sarcoma. JClin Oncol (Meeting Abstracts) 2012, 30:10041.
34. Ng J.M., Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer 2011, 11:493-501.
35. Ranganathan P., Weaver K.L., Capobianco A.J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 2011, 11:338-351.
36. Roma J., Masia A., Reventos J., et al. Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility invitro. Clin Cancer Res 2011, 17:505-513.
37. Tanaka M., Setoguchi T., Hirotsu M., et al. Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 2009, 100:1957-1965.
38. Ban J., nani-Baiti I.M., Kauer M., et al. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res 2008, 68:7100-7109.
39. Kelleher F.C., Cain J.E., Healy J.M., et al. Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. Pharmacol Ther 2012, 136:153-168.
40. Wang C.Y., Wei Q., Han I., et al. Hedgehog and Notch signaling regulate self-renewal of undifferentiated pleomorphic sarcomas. Cancer Res 2012, 72:1013-1022.
41. Gounder M.M., Dickson M.A., Wu N., et al. Afirst-in-human, phase Ib combination study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a hedgehog inhibitor, GDC-0449, with a Notch inhibitor, RO4929097, in patients with advanced sarcoma. JClin Oncol (Meeting Abstracts) 2012, 30:10004.
42. Ray-Coquard I., Italiano A., Bompas E., et al. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist 2012, 17:260-266.
43. Antonescu C.R., Yoshida A., Guo T., et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res 2009, 69:7175-7179.
44. D'Angelo S.P., Antonescu C.R., Keohan M.L., et al. Activity of sorafenib in radiation-associated breast angiosarcomas harboring MYC and FLT4 amplifications. JClin Oncol (Meeting Abstracts) 2012, 30:10019.
45. Chevreau C., Le Cesne A., Ray-Coquard I., et al. Phase II study of sorafenib mesylate (So) in patients (pts) with evolutive and advanced epithelioid hemangioendothelioma (EHE) or hemangiopericytoma/solitary fibrous tumor (SFT). JClin Oncol (Meeting Abstracts) 2012, 30:10020.
46. Stacchiotti S., Negri T., Libertini M., et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol 2012, 23:3171-3179.
47. Levard A., Derbel O., Meeus P., et al. Outcome of patients with advanced solitary fibrous tumors: the Centre Leon Berard experience. BMC Cancer 2013, 13:109.
48. Azizi A.A., Haberler C., Czech T., et al. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol 2006, 7:521-523.
49. Stacchiotti S., Negri T., Zaffaroni N., et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol 2011, 22:1682-1690.
50. Gardner K., Judson I., Leahy M., et al. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. JClin Oncol (Meeting Abstracts) 2009, 27:10523.
51. Kummar S., Allen D., Monks A., et al. Cediranib for metastatic alveolar soft part sarcoma. JClin Oncol 2013, 31(18):2296-2302.
52. Ray-Coquard I., Blay J.Y., Italiano A., et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012, 13:1133-1140.
53. Dickson M.A., Tap W.D., Keohan M.L., et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013, 31(16):2024-2028.
54. McCormack F.X., Inoue Y., Moss J., et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. NEngl J Med 2011, 364:1595-1606.
55. El-Hashemite N., Zhang H., Henske E.P., et al. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 2003, 361:1348-1349.
56. Pan C.C., Chung M.Y., Ng K.F., et al. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma. JPathol 2008, 214:387-393.
57. Kenerson H., Folpe A.L., Takayama T.K., et al. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol 2007, 38:1361-1371.
58. Wagner A.J., Malinowska-Kolodziej I., Morgan J.A., et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. JClin Oncol 2010, 28:835-840.
59. Italiano A., Delcambre C., Hostein I., et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol 2010, 21:1135-1137.
60. Pedersen J.V., Benson C., Tunariu N., et al. Aretrospective study from the Royal Marsden Hospital (RMH) of patients with malignant perivascular epithelioid cell tumors (PEComa) receiving treatment with sirolimus (SI) or temsirolimus (TSI). JClin Oncol (Meeting Abstracts) 2012, 30:10038.
61. Subbiah V., Trent J.C., Kurzrock R. Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. JClin Oncol 2010, 28:e415.
62. Macarulla T., Cervantes A., Elez E., et al. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther 2010, 9:2844-2852.
63. Matulonis U.A., Sharma S., Ghamande S., et al. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol 2012, 127:63-69.